Meanwhile, the S&P BSE Sensex was up 132.36 points or 0.71% at 18,863.52.
On BSE, 50,000 shares were traded in the counter as against average daily volume of 63,344 shares in the past one quarter.
The stock hit a high of Rs 137.50 and a low of Rs 131.15 so far during the day. The stock had hit a 52-week low of Rs 78.50 on 18 October 2012. The stock had hit a 52-week high of Rs 176 on 17 April 2012.
The stock had outperformed the market over the past one month till 17 April 2013, surging 16.75% compared with the Sensex's 3.58% fall. The scrip had also outperformed the market in past one quarter, jumping 31.63 % as against Sensex's 6.18% fall.
The small-cap company has equity capital of Rs 15.82 crore. Face value per share is Re 1.
Fresenius Kabi (Singapore) Pte (FKSL), the promoter shareholder of Fresenius Kabi Oncology before market today, 18 April 2013, has expressed its intention to pay an indicative price of up to Rs 130 per share to acquire the shares offered to it in the Delisting Offer, subject to FKSL's right under the Delisting Regulations to accept or reject any price discovered under the reverse book building process set forth therein. The indicative price of Rs 130 per share is at a discount of 3.12% compared to Fresenius Kabi Oncology's closing price of Rs 134.20 on Wednesday, 17 April 2013.
Fresenius Kabi Oncology during trading hours on Wednesday, 17 April 2013, said it has received a letter dated 16 April 2013 from its foreign parent -- Fresenius FKSL -- notifying the company of its intention to make a voluntary delisting offer to the public shareholders of the company to acquire the entire public shareholding of the company of 3.06 crore equity shares of Re 1 each, representing 19% of the share capital of the company and delist the equity shares of the company from the stock exchanges on which the equity shares of the company are presently listed, i.e., BSE and the National Stock Exchange of India. The stock had surged 5.62% to settle at Rs 134.20 on Wednesday, 17 April 2013.
Fresenius Kabi Oncology's net profit galloped 3354.3% to Rs 48.36 crore on 35.9% growth in net sales to Rs 150.38 crore in Q3 December 2012 over Q3 December 2011.
Fresenius Kabi Oncology is engaged in cancer research and development of anti-cancer products. The company manufactures active pharmaceutical ingredients (APIs), intermediates and oral & injectable finished dosage forms.
Powered by Capital Market - Live News
